Infant Bacterial Therapeutics (SE:IBT.B)
:IBT.B
Top Page
Infant Bacterial Therapeutics AB
(IBT.B)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr48.00
▼(-23.81% Downside)
Action:ReiteratedDate:12/30/25
The score is driven primarily by weak financial performance (persistent losses and negative cash flow with increasing burn), partially mitigated by a debt-free balance sheet. Technicals are mixed with neutral momentum but a broader downtrend versus longer-term averages, and valuation is constrained by negative earnings and no dividend support.
Infant Bacterial Therapeutics AB (IBT.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr673.57M
Dividend YieldN/A
Average Volume (3M)13.37K
Price to Earnings (P/E)―
Beta (1Y)-0.09
Revenue GrowthN/A
EPS Growth44.65%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.43
Shares Outstanding13,018,137
10 Day Avg. Volume5,917
30 Day Avg. Volume13,366
Financial Highlights & Ratios
PEG Ratio-2.50
Price to Book (P/B)4.24
Price to Sales (P/S)180517.03
P/FCF Ratio-6.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Infant Bacterial Therapeutics AB Business Overview & Revenue Model
Company Description
Infant Bacterial Therapeutics AB (IBT.B) is a Swedish biopharmaceutical company focused on developing and commercializing drugs to prevent or treat diseases affecting premature infants. The company operates primarily in the healthcare and biotechn...
How the Company Makes Money
Infant Bacterial Therapeutics AB generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is centered around licensing agreements, research and development collaborations...
Infant Bacterial Therapeutics AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
74
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -1.00K | 4.00K | 77.00K | 12.00K | 0.00 | 0.00 |
| Gross Profit | -1.00K | 4.00K | 77.00K | 12.00K | 0.00 | 0.00 |
| EBITDA | -101.51M | -136.91M | 11.55M | -64.34M | -43.76M | -70.89M |
| Net Income | -102.33M | -136.91M | -123.07M | -65.45M | -44.99M | -72.31M |
Balance Sheet | ||||||
| Total Assets | 193.23M | 239.57M | 351.33M | 349.62M | 408.48M | 450.32M |
| Cash, Cash Equivalents and Short-Term Investments | 176.32M | 223.39M | 329.06M | 335.84M | 386.75M | 423.44M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 58.88M | 69.30M | 46.18M | 17.91M | 13.22M | 10.16M |
| Stockholders Equity | 134.35M | 170.26M | 305.15M | 331.71M | 395.25M | 440.15M |
Cash Flow | ||||||
| Free Cash Flow | -102.84M | -113.13M | -101.22M | -85.80M | -55.62M | -58.39M |
| Operating Cash Flow | -102.84M | -113.13M | -101.22M | -85.80M | -55.62M | -58.39M |
| Investing Cash Flow | 0.00 | 0.00 | -4.15M | -1.00K | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | 2.01M | 96.52M | 1.88M | 91.00K | 1.76M |
Infant Bacterial Therapeutics AB Technical Analysis
Positive
63.00
Price Trends
50.61
Negative
49.79
Positive
54.38
Negative
Market Momentum
-0.18
Negative
51.06
Neutral
64.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Positive. The current price of 63 is above the 20-day moving average (MA) of 49.24, above the 50-day MA of 50.61, and above the 200-day MA of 54.38, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 51.06 is Neutral, neither overbought nor oversold. The STOCH value of 64.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IBT.B.
Infant Bacterial Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | kr986.99M | 7.07 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr673.57M | -10.44 | -46.42% | ― | ― | 44.65% | |
46 Neutral | kr150.42M | -44.78 | -16.90% | ― | 4.64% | ― | |
45 Neutral | kr300.05M | -1.89 | -16.51% | ― | ― | 31.37% | |
44 Neutral | kr366.65M | -6.44 | -79.60% | ― | ― | 31.62% | |
42 Neutral | kr24.20M | -0.24 | -186.13% | ― | ― | 0.30% |
* Healthcare Sector Average
SE:IBT.B
Infant Bacterial Therapeutics AB
50.00
-5.80
-10.39%
SE:XBRANE
Xbrane Biopharma AB
7.30
-17.33
-70.36%
SE:ACE
Ascelia Pharma AB
2.89
0.15
5.47%
SE:GUARD
Guard Therapeutics International AB
1.20
-11.05
-90.20%
SE:IMMU
Immunicum AB
4.90
0.10
2.08%
SE:CANTA
Cantargia AB
3.97
2.67
205.38%
Infant Bacterial Therapeutics AB Corporate Events
Infant Bacterial Therapeutics Partners with BioConnection for Drug Production
Dec 11, 2025
Infant Bacterial Therapeutics AB has partnered with BioConnection to advance the production of their lead drug, IBP-9414, by initiating Process Performance Qualification at BioConnection’s facility in the Netherlands. This collaboration is c...
IBT Pursues Accelerated Approval for IBP-9414 After FDA Discussions
Nov 25, 2025
Infant Bacterial Therapeutics AB has decided to pursue an accelerated approval pathway for its live biotherapeutic product, IBP-9414, following discussions with the FDA. This decision allows for expedited approval of the drug, which has shown sign...
Infant Bacterial Therapeutics Partners with Recipharm for IBP-9414 Production
Nov 20, 2025
Infant Bacterial Therapeutics AB has partnered with Recipharm Advanced Bio to initiate the Process Performance Qualification (PPQ) for its lead product, IBP-9414, at Recipharm’s facility in Cuxhaven, Germany. This collaboration marks a signi...
Infant Bacterial Therapeutics Advances IBP-9414 Amid Financial Challenges
Nov 13, 2025
Infant Bacterial Therapeutics AB reported no net sales and a reduced operating loss for the third quarter of 2025, reflecting ongoing investment in their lead product, IBP-9414. The company achieved a significant milestone with the FDA granting Br...
Infant Bacterial Therapeutics AB Forms Nomination Committee for 2026 AGM
Oct 20, 2025
Infant Bacterial Therapeutics AB has announced the formation of its Nomination Committee for the 2026 Annual General Meeting. The committee, which includes representatives from the company’s three largest shareholders, will play a crucial ro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.